The Pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Alkoxysilyl compounds. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and alkoxysilyl compounds are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Alkoxysilyl compounds is a key innovation area in pharmaceutical
Alkoxysilyl compounds are siloxane-based nanomaterials used in molecular assembly, nano-building block linkage, and in oligosiloxane compound synthesis. They are used in various applications such as pharmaceuticals, herbicides, and insecticides.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 40+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of alkoxysilyl compounds.
Key players in alkoxysilyl compounds – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to alkoxysilyl compounds
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Scipharm||49||Unlock company profile|
|Shin-Etsu Chemical||46||Unlock company profile|
|LG||43||Unlock company profile|
|Uni-President China Holdings||40||Unlock company profile|
|Henkel||35||Unlock company profile|
|KCC||33||Unlock company profile|
|DR. Alexander Wacker Familiengesellschaft MIT Beschraenkter Haftung||33||Unlock company profile|
|Ocuphire Pharma||30||Unlock company profile|
|Incyte||28||Unlock company profile|
|Shikoku Chemicals||28||Unlock company profile|
|United Therapeutics||25||Unlock company profile|
|RAG-Stiftung||25||Unlock company profile|
|BASF||24||Unlock company profile|
|Eisai||22||Unlock company profile|
|Zhejiang Ausun Pharmaceutical||19||Unlock company profile|
|Dow||19||Unlock company profile|
|Lanxess||19||Unlock company profile|
|Sekisui Chemical||18||Unlock company profile|
|3M||15||Unlock company profile|
|Gedeon Richter||14||Unlock company profile|
|E. Merck||13||Unlock company profile|
|Silecs||11||Unlock company profile|
|Goodyear Tire & Rubber||10||Unlock company profile|
|Grupo Kuo SAB de CV||10||Unlock company profile|
|Chirogate International||10||Unlock company profile|
|Sigilon Therapeutics||10||Unlock company profile|
|Fabbrica Italiana Sintetici||10||Unlock company profile|
|Arbutus Biopharma||9||Unlock company profile|
|Jingzhou Jianghan Fine Chemical||9||Unlock company profile|
|Nissan Chemical||9||Unlock company profile|
|Arkema||8||Unlock company profile|
|Yonsung Fine Chemicals||8||Unlock company profile|
|CEKO||8||Unlock company profile|
|HEC Pharm Group||8||Unlock company profile|
|Albemarle||8||Unlock company profile|
|Lunan Pharmaceutical Group||6||Unlock company profile|
|Ivoclar Vivadent||6||Unlock company profile|
|Agilent Technologies||6||Unlock company profile|
|Huntsman||6||Unlock company profile|
|Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung||6||Unlock company profile|
|Atotech||5||Unlock company profile|
|Shofu||5||Unlock company profile|
|Wanhua Chemical Group||5||Unlock company profile|
|CVC Capital Partners SICAV-FIS||5||Unlock company profile|
|Seino Holdings||5||Unlock company profile|
Source: GlobalData Patent Analytics
Scipharm is the leading patent filer for Alkoxysilyl compounds. Trepulmix (Treprostinil), which is one of the company’s marketed drugs, is manufactured by using this compound. Shin-Etsu Chemical and LG are the other key patent filers for Alkoxysilyl compounds.
In terms of application diversity, Sigilon Therapeutics is the top company, followed by Albemarle and Seino. By means of geographic reach, Ocuphire Pharma held the top position. Scipharm and Lanxess stood in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.